An increasing emphasis on prevention is shifting the mindset around pediatric nephrology, and findings from ongoing studies will further expand the evidence base, said Tammy Brady, MD, PhD, medical director of the Pediatric Hypertension Program and associate professor of pediatrics at Johns Hopkins University.
An increasing emphasis on prevention is shifting the mindset around pediatric nephrology, and findings from ongoing studies will further expand the evidence base, said Tammy Brady, MD, PhD, medical director of the Pediatric Hypertension Program and associate professor of pediatrics at Johns Hopkins University.
Transcript
What have been the most significant recent discoveries or advances in pediatric nephrology?
So I think in regards to metabolic syndrome and cardiovascular health, really, I think the biggest thing has been this new idea of cardiovascular health promotion, and this concept of ideal cardiovascular health.
And in fact, with the new American Academy of Pediatrics clinical practice guidelines, I think this is a great example. I mean, this massive document details all of the evidence to support their recommendations for regular screening, early diagnosis, and treatment of pediatric hypertension, which really has promised to have a significant impact in the future health of our future adults.
The American Heart Association and other professional organizations also are pushing forward this concept, more prevention, so primordial prevention, meaning preventing the development of risk factors from ever becoming manifest in the first place, recognizing that there’s a life span approach to chronic disease and we really as pediatricians need to work early and hard at preventing these risk factors from ever developing.
I think this shift in mindset has really sparked a lot of really cool and interesting research that will move the field forward. I’m particularly excited to see the results of the SHIP-AHOY [Study of High Blood Pressure in Pediatrics: Adult Hypertension Onset in Youth] study, which is working to find what blood pressure, among other things, but what blood pressure thresholds really associate with intermediate outcomes in children, because right now, we’re using epidemiologic cutoffs to diagnose hypertension and manage treatment. And hopefully, this study will give us some more real evidence base as to what blood pressure thresholds we really should be targeting because that’s what’s going to have the most impact in terms of outcomes. So I think there’s been a lot of advances, but I think in the next 5 years, we’re going to be seeing even more exciting things coming through.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More